Nanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems
Rhea-AI Summary
Nano X Imaging (NASDAQ: NNOX) said its U.S. unit Nanox Impact signed a distribution agreement with NuvioDx to support deployment of Nanox.ARC systems across clinical sites in multiple states. The Nanox.ARC is an FDA-cleared multisource digital tomosynthesis system that aims to enable 3D imaging at lower cost and reduced radiation dose versus traditional CT.
The deal expands Nanox’s 2026 U.S. distribution framework and channel partner strategy to broaden regional market access and sustained system utilization.
Positive
- Signed U.S. distribution agreement with NuvioDx to support Nanox.ARC deployment
- Nanox.ARC is FDA-cleared for multisource digital tomosynthesis (3D imaging)
- Expands 2026 U.S. channel partner framework to increase regional market access
Negative
- No financial terms, volumes, or definitive timelines disclosed for the NuvioDx agreement
- Geographic scope limited to unspecified "various states" without site counts or commitments
News Market Reaction – NNOX
In the May 4 session, NNOX gained 8.09%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Distribution agreement | Positive | -14.3% | New U.S. distribution deal to expand Nanox.ARC deployments across clinical sites. |
| Apr 20 | Commercial rollout deal | Positive | -24.4% | Agreement to deploy 300 Nanox.ARC systems in the U.S. over several years. |
| Apr 20 | Earnings and update | Negative | -24.4% | Q4 2025 loss with impairment and restructuring tied to Korean manufacturing. |
| Apr 16 | Product design award | Positive | +4.6% | Nanox.ARC X won 2026 Red Dot Product Design award for compact 3D system. |
| Apr 14 | Clinical collaboration | Positive | +3.8% | Collaboration to study Nanox.ARC for emergency orthopedic imaging versus CT and X-ray. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Commercial distribution agreements have previously seen negative price reactions, while clinical collaborations and product recognition news tended to align with positive price moves.
Over the past weeks, Nanox reported multiple milestones around its Nanox.ARC platform, including U.S. distribution deals, a collaboration for an orthopedic imaging clinical study, and a design award for Nanox.ARC X. Despite these commercial wins, the April 20 commercial agreement and April 23 distribution news saw double-digit percentage declines, contrasting with positive reactions to the April 14 clinical collaboration and April 16 Red Dot award. Today’s NuvioDx distribution agreement extends this U.S. channel build-out theme.
Key Terms
digital tomosynthesis medical
fda-cleared regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Advances Nanox’s ongoing U.S. commercialization and deployment efforts
PETACH TIKVA, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Nano X Imaging Ltd. (“Nanox”, or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a distribution agreement with NuvioDx LLC (“NuvioDx”), an imaging solutions provider focused on expanding access to diagnostic imaging, to support the deployment of Nanox.ARC systems.
This agreement represents Nanox’s growing distribution framework announced in 2026, following recent agreements, as the company continues to advance its channel partner strategy and build a diversified distribution network across the United States.
Under the terms of the agreement, NuvioDx will support the deployment of Nanox.ARC multi-source digital tomosynthesis systems across clinical sites in various states. The collaboration reflects Nanox’s strategy of working with partners that bring regional market access and operational capabilities to support system deployment and sustained utilization.
The Nanox.ARC is an FDA-cleared, multisource digital tomosynthesis system that makes 3D imaging possible in more clinical settings, at a lower cost and reduced radiation dose compared to traditional CT.
“This collaboration represents an important step in strengthening our commercialization strategy and expanding our channel partner network,” said Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox. “NuvioDX brings meaningful experience in supporting market adoption of innovative medical imaging technologies, which aligns with our efforts to broaden access to imaging.”
“NuvioDX is excited about the opportunity to partner with Nano X Imaging Ltd. and bring cutting-edge, innovative healthcare technology solutions to the marketplace,” said Richard Gastineau, Managing Director of NuvioDx LLC. “We believe Nano X Imaging Ltd.’s technology is strongly positioned to help providers enhance patient care, improve outcomes, and ultimately contribute to a better quality of life for the communities they serve.”
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision.
About NuvioDX
NuvioDx LLC is a healthcare technology commercialization partner specializing in medical imaging, diagnostic, and related healthcare solutions. Headquartered in Philadelphia, the company is led by experienced industry professionals with more than 25 years of expertise. NuvioDx works with technology providers, healthcare organizations, and clinical partners to drive go-to-market execution, operational readiness, customer adoption, and long-term commercial growth across real-world healthcare environments. Additional information is available at: https://nuviodx.com/
Forward-Looking Statements
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox’s ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xii) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xiii) potential litigation associated with our transactions.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
Contacts
Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com
